TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Combined outcome measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BSI global measure of distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Excellence rate of anesthetic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction of anesthetic effect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lavage quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of intoxication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who discontinued treatment because of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in serum creatinine levels to more than 30% above baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: improvement in OAB symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine nephrin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difficulty of passing the scope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain or discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in plaque formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Corneal staining reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: OSDI score reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Redness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Surface temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: total respiratory support time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: motor skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower analgesic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of contraceptives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of well-child care visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injury rates in children
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in dysmotility-like subtype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fluid shift volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent BMD change in hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent BMD change in spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 12-month nonsmoking rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost per life-year saved
Endpoint domain: Resource use
Primary endpoint: Quality-adjusted life-years (QALYs) saved
Endpoint domain: Resource use
Primary endpoint: Rate of successful clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge and attitudes related to diet and physical activity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in physical or emotional health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in health behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in health indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of tube insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of total combined thiols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of inflammatory indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of oxidative stress indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in day and night pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of delirium
Endpoint domain: Adverse events/effects
Primary endpoint: dose of fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage change in FEV(1) from baseline to week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total Neurobehavioral Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agitation/aggression factor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lability/tension factor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost-effectiveness per fall prevented
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cost-effectiveness per extra person avoiding mobility deterioration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cost-effectiveness per quality-adjusted life year gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pause-dependent augmentation of J waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean bond strength values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of rise in SCr of >25%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Subcutaneous fibrosis (grade 2 or greater)
Endpoint domain: Adverse events/effects
Primary endpoint: Telengectasia (grade 2 or greater)
Endpoint domain: Adverse events/effects
Primary endpoint: Breast atrophy (grade 2 or greater)
Endpoint domain: Adverse events/effects
Primary endpoint: Skin pigmentation (grade 3 or greater)
Endpoint domain: Adverse events/effects
Primary endpoint: Pain load reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: FEV1 decline rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Saint George Respiratory Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of synechia formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3-4 reversible musculoskeletal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Quality Adjusted Life Years (QALY) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Survival difference between hemodialysis and peritoneal dialysis
Endpoint domain: Mortality/survival
Primary endpoint: Area under the concentration-time curve (AUC)/MIC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of dentin hypersensitivity (DH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability of Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: median decrease in pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dyspeptic symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half time (T1/2) gastric emptying (GE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Inter- and intraobserver agreement for visual detection of mild emphysema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of risky drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of AEP risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative morphine use at 24 hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SEIQOL-DW variance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ANS and metabolic counterregulatory responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical cure rate on day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36BP
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: FACT/GOG-Ntx scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BPI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients' functional outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Arterial mean dye bolus velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Capillary blood velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Arteriovenous passage time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Appendicular lean mass preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Learning improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: perceived greater control over preventing diabetes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reported having eaten more healthily
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: increase in volume of milk production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best-corrected visual acuity of 20/40 or better at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital survival rates
Endpoint domain: Mortality/survival
Primary endpoint: severity of illness (organ system failures)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endotoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of SOS
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of DILI
Endpoint domain: Adverse events/effects
Primary endpoint: overall nutrition scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum levels of zinc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Antioxidant status (TAC, GSH, SOD activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjective fatigue scale improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of patients with HbA1c < 7.0% without hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean peak FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean trough FEV1 on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of vascular injuries during epidural catheter insertion
Endpoint domain: Adverse events/effects
Primary endpoint: 24 hr PCA morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: headache days/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: migraine days/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(last) of glimepiride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nt-proBNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difficulty score during spinal anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean arterial pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response rate to MTX therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse rate by 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year rates of death/infarction
Endpoint domain: Mortality/survival
Primary endpoint: bradykinin-induced t-PA release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: degree of change in depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: likelihood of depression recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: likelihood of anti-depressant induced switching
Endpoint domain: Adverse events/effects
Primary endpoint: participant response to CGT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of suicidal ideation
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of infection with T. parva
Endpoint domain: Adverse events/effects
Primary endpoint: Mean MD slopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neonatal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Laxation within 4 hours after first dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Laxation without rescue laxative within 4 hours after two or more doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median time to laxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time to cessation of new lesion formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean constitutional illness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot and Ankle Ability Measure-Sport subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear-Avoidance Beliefs Questionnaire Physical Activity subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CGI‐EI changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: necessary clinical adjustments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: burden of side effects frequency
Endpoint domain: Adverse events/effects
Primary endpoint: VO2 on-kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: anaerobic contribution to exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL-C reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: muscle jump velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma IL-6 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 14th day mortality
Endpoint domain: Mortality/survival
Primary endpoint: Thymic index at 52 weeks of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Significant fibrosis identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced adherence of uropathogenic E. coli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recurrent chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of invasive candidiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: QTd decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QTcd decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Forearm responses to nitroprusside and acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time on the obstacle course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major adverse cardiac and cerebrovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: repeat revascularization
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical reactivity to shrimp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative global QoR‐40 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total amount of tramadol during 24 h after surgery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: serum intact PTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: clinically significant prostate cancer diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: IL-6 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inotropic scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systemic ventricle mean delta strain values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal abstinence scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brazelton scores for habituation, social-interactive, motor and autonomic clusters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of cardiovascular diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence rates of gout attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of treatment-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of treatment-related grade 2-4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with grade 3/4 liver enzyme elevations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: disease status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Greater expression of inflammatory cells (CD45-positive cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increased immunostaining of MMP 8 and MMP 9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H. pylori eradication efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemorrhage recurrence rate
Endpoint domain: Adverse events/effects
Primary endpoint: remission rates after 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's dietary preferences (fruit over candy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to CRC screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of FOBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depressive symptoms measured by SCL-90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depressive symptoms measured by BDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maternal fasting blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Completion time of the switching condition of the modified Stroop test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual-task cost in the divided attention task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of phlebitis or infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of pockets >5 mm deep remaining above that level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pocket depths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer continuing to bleed on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in concept formation performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased activity and quicker psychomotor test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in affect, cooperation, and engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients achieving response at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean ratio of early to late transmitral flow velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Minnesota Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life